Recursion Pharmaceuticals
clinical intracranial threatens mortality if amenable surgical excision is primary intervention many patients have multiple that exhibit heterogenous behavior and asynchronous growth stasis or shrinkage of tumor could improve prognosis disease overview neurofibromatosis type | Recursion Pharmaceuticals
Company
Deck Type
Sector
Industry
Deck date
January 2023
Slide
98 of 143
Related slides by other companies
Alkermes
Investor Presentation
March 2023
clinical development plan designed to rapidly advance program in | Alkermes
BioAtla
Investor Presentation
January 2024
phase cab demographics tumor types | BioAtla
Kymera
Investor Presentation
December 2023
partial response and stable disease observed across multiple tumor types during dose of | Kymera
BioNTech
Results
August 2021
global phase clinical trial in anti melanoma patients | BioNTech
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io